DISMANTLING THE FDA
TOBRAMYCIN SERUM CONCENTRATIONS AFTER AEROSOL AND ORAL ADMINISTRATION IN CYSTIC FIBROSIS
LOCALIZATION OF 99mTc-LABELED ApoB SYNTHETIC PEPTIDE IN ARTERIAL LESIONS OF AN EXPERIMENTAL MODEL OF SPONTANEOUS ATHEROSCLEROSIS
A NONPARAMETRIC ALTERNATIVE TO MODELING POPULATION PHARMACOKINETICS IN PATIENTS WITH SPINAL CORD INJURY
EVALUATION OF BINDING EQUATION METHOD FOR UNBOUND SERUM CONCENTRATION PREDICTION OF VALPROIC ACID IN POLYTHERAPY PEDIATRIC PA TIENTS WITH EPILEPSY
PHARMACOKINETICS IN NON-INSULIN-DEPENDENT DIABETICS OF THE ALDOSE REDUCTASE INHIBITOR, ZOPOLRESTAT
POINT-COUNTERPOINT SERIES
NEW ACCELERATED rt-PA STRATEGY HAS SUFFICIENT ADVANTAGE OVER OLDER STREPTOKINASE STRATEGIES THAT IT SHOULD BE THE THROMBOLYTIC STRATEGY OF CHOICE IN ANTERIOR AND LARGE INFARCTIONS
STREPTOKINASE IS STILL THE AGENT OF CHOICE FOR MOST PATIENTS WITH MYOCARDIAL INFARCTION
ROUTINE, EARLY, CORONARY ANGIOGRAPHY FOLLOWING THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION
CORONARY ARTERIOGRAPHY SHOULD NOT BE ROUTINELY USED POSTINFARCTION IN PATIENTS HAVING RECEIVED THROMBOLYTIC THERAPY
PRIMARY ANGIOPLASTY IS THE OPTIMAL APPROACH TO EARLY REPERFUSION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
THE RELATIVE MERITS OF DIRECT ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYTIC THERAPY FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION